Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APOE ε4-related structural vulnerability in mild cognitive impairment: a subsystem-based analysis of the default mode network.

Research square·2026
Same author

Disentangling global atrophy burden from local structural patterns reveals clinically relevant heterogeneity in mild cognitive impairment.

Research square·2026
Same author

TGF-β1 Promotes the Recovery of Dorsal Root Ganglion Neurons from Cisplatin-Induced Injury Through Smad4-Dependent Mechanism.

Current issues in molecular biology·2026
Same author

A novel L-shaped ortho-quinone analog and 2-Deoxy-D-Glucose a synergistic approach to inhibit hepatocellular carcinoma cell proliferation.

Scientific reports·2026
Same author

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Journal of medicinal chemistry·2026
Same author

Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity.

Future medicinal chemistry·2026

Related Experiment Video

Updated: Jun 13, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Development of MPS1 Inhibitors: Recent Advances and Perspectives.

Yangjie Zeng1, Xiaodong Ren1, Pengyao Jin1

  • 1Medical College, Guizhou University, Guiyang, Guizhou 550025, China.

Journal of Medicinal Chemistry
|December 14, 2023
PubMed
Summary

Monopolar spindle kinase 1 (MPS1) is crucial for cell division and often overexpressed in cancers. Inhibiting MPS1 shows promise for cancer therapy, but developing effective drugs remains challenging.

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

328

Related Experiment Videos

Last Updated: Jun 13, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

328

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Drug Discovery

Background:

  • Monopolar spindle kinase 1 (MPS1) is a dual-specificity kinase essential for mitosis, regulating spindle assembly checkpoint (SAC) activation and sister chromatid separation.
  • MPS1 overexpression is linked to aneuploidy and survival in various human cancers, making it a significant therapeutic target.
  • Despite its therapeutic potential, challenges remain in developing clinically approved MPS1 inhibitors.

Purpose of the Study:

  • To provide an overview of MPS1's structure, function, and role in cancer.
  • To explore structure-activity relationships, selectivity, and pharmacokinetics of diverse MPS1 inhibitors.
  • To review strategies for enhancing MPS1 inhibitor selectivity for improved cancer treatment.

Main Methods:

  • Literature review of MPS1's role in cancer.
  • Analysis of structure-activity relationships for various MPS1 inhibitor scaffolds.
  • Examination of pharmacokinetic properties and selectivity enhancement strategies for MPS1 inhibitors.

Main Results:

  • MPS1's overexpression contributes to tumor cell survival by reducing SAC sensitivity.
  • Numerous MPS1 inhibitors with diverse scaffolds have been identified, but clinical translation is limited.
  • Strategies to improve inhibitor selectivity are crucial for developing potent small-molecule drugs.

Conclusions:

  • MPS1 is a validated cancer target due to its role in mitosis and aneuploidy.
  • Further research into MPS1 inhibitor selectivity and pharmacokinetics is essential for clinical success.
  • Developing novel, highly potent small-molecule MPS1 inhibitors holds promise for future cancer therapies.